Lisdexamfetamine

Pediatric Drugs

Volumn 9, Issue 2, 2007, Pages 129-135

  Blick, Stephanie K A ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; AMPHETAMINE; CYTOCHROME P450; LISDEXAMFETAMINE; PLACEBO; UNCLASSIFIED DRUG; VYVANSE;

ANOREXIA; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABUSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDICATION; DRUG MECHANISM; DRUG RELEASE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; NAUSEA; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT; XEROSTOMIA;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS; DEXTROAMPHETAMINE; HUMANS;

EID: 34247254387     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709020-00007     Document Type: Review

References (21)

1. Buitelaar JK, Montgomery SA, van Zwieten-Boot BJ. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol 2003 Aug; 13 (4): 297-304
2. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement. Pediatrics 2001; 108 (4): 1033-44
3. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004 Jan; 14 (1): 11-28
4. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdex-amfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007 Mar; 29 (3): 1-14
5. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998 Jul; 94 (1): 127-52
6. Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 2004; 18 (14): 1011-30
7. de La Torre R, Farŕe M, Navarro M, et al. Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet 2004; 43 (3): 157-85
8. Wilens TE. Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs 2003; 63 (22): 2395-411
9. Jasinski D, Krishnan S. A double-blind, randomized, placebo- and active-controlled, 6-period crossover study to evaluate the likability, safety, and abuse potential of lisdexamfetamine dimesylate (LDX) in adult stimulant abusers [poster]. 2006 US Psychiatric & Mental Health Congress; 2006 Nov 18; New Orleans (LA)
10. Jasinski D, Krishnan S. Abuse liability of intravenous lisdexamfetamine dimesylate (LDX; NRP104) [poster]. 2006 US Psychiatric and Mental Health Congress; 2006 Nov 17; New Orleans (LA)
11. Krishnan S, Moncrief S. An evaluation of the CYP450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 2007; 35: 180-4
12. Boyle L, Moncrief S, Krishnan S. Pharmacokinetics of NRP 104 (lisdexamfetamine dimesylate) following administration of a single intranasal, intravenous, or oral dose in rats [poster]. 46th Annual New Clinical Drug Evaluation Unit Meeting; 2006 Jun 14; Boca Raton (FL)
13. Krishnan S. A multiple-dose single-arm pharmacokinetics study of oral lisdexamfetamine (LDX; NRP104) in healthy adult volunteers [poster]. 46th Annual New Clinical Drug Evaluation Unit Meeting; 2006 Jun 14; Boca Raton (FL)
14. Jasinski D, Krishnan S. Pharmacokinetics of oral lisdexamfetamine dimesylate (LDZ; NRP104) vs d-amphetamine in healthy adults with a history of stimulant abuse [poster]. 2006 US Psychiatric and Mental Health Congress; 2006 Nov 17; New Orleans (LA)
15. Krishnan S, Ermer JC, Kehner G, et al. Effect of food on lisdexamfetamine dimesylate (LDX; NRP104) pharmacokinetics [poster]. 2006 US Psychiatric & Mental Health Congress; 2006 Nov 18; New Orleans (LA)
16. New River Pharmaceuticals Inc. Protocol NRP104.A02. Vol. 63, Mod 5, 5.3.5.4.2: 1262. (Data on file)
17. Biederman J, Boellner S, Childress A, et al. Improvements in symptoms of ADHD in school-aged children with lisdexamfetamine (SPD489/NPR104) and extended-release mixed amphetamine salts versus placebo [abstract no. NR631 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto
18. Lopez FA, Boellner SW, Childress A, et al. ADHD symptom improvement in children treated with lisdexamfetamine dimesylate (LDX) [poster]. 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2006 28 October; San Diego (CA)
19. Childress AC, Krishnan S, McGough JJ, et al. Interim analysis of a long-term, open-label, single-arm study of lisdexamfetamine (LDX), an amphetamine prodrug, in children with ADHD [poster]. 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2006; San Diego (CA)
20. Data on file, Shire Development Inc., 2007 Feb 15
21. US FDA. Lisdexamfetamine (Vyvanse™): prescribing information (US) [online]. Available from URL: http://www.fda.gov [Accessed 2007 Mar 1]